secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2023-05-19T23:59:59+00:00
Accession:  0001193125-23-149302
Event type: litigation
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal settles derivative suit over KSP acquisition; royalty cut, governance changes
--------------------------------------------------------------------------------

- Amneal agreed to reduce Kashiv royalties by 1.15% on three products until $11.5M NPV cap is reached.
- Attorneys' fees capped at $2M, subject to court approval; settlement hearing set for July 25, 2023.
- Governance changes include independent Delaware counsel for related-party transactions and stockholder vote on deals >$100M.
- Deborah M. Autor added to Amneal board and Conflicts Committee as independent director.
- Settlement resolves claims that 2021 KSP acquisition was unfair; no admission of wrongdoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000119312523149302/0001193125-23-149302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000119312523149302/d484910d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-149302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer